Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

Régis Peffault de Latour, Robert A. Brodsky, Stephan Ortiz, Antonio M. Risitano, Jun H. Jang, Peter Hillmen, Alexander D. Kulagin, Austin G. Kulasekararaj, Scott T. Rottinghaus, Rasha Aguzzi, Xiang Gao, Richard A. Wells, Jeff Szer

Research output: Contribution to journalArticle

Abstract

Ravulizumab, a novel long-acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non-inferior to eculizumab for all efficacy outcomes in two randomised, open-label, phase 3 trials in C5 inhibitor-naïve (Study 301) and eculizumab-experienced (Study 302) adult patients with paroxysmal nocturnal haemoglobinuria (PNH). This pre-specified analysis characterised ravulizumab pharmacokinetics (PK), pharmacodynamics (PD; free C5 levels), and PD differences between medications (Study 301, n = 246; Study 302, n = 195). Ravulizumab PK parameters were determined using non-compartmental analysis. Serum free C5 was quantified with a Gyros-based fluorescence assay (ravulizumab) and an electrochemiluminescence ligand-binding assay (eculizumab). Ravulizumab PK parameters were numerically comparable in both studies; the median time to maximum concentrations ranged from 2·3 to 2·8 and 2·3 to 2·6 h in studies 301 and 302, respectively. Ravulizumab steady-state serum concentrations were achieved immediately after the first dose and sustained throughout treatment. For ravulizumab, the mean (SD) post hoc terminal elimination half-life was 49·7 (8·9) days. Serum free C5 concentrations <0·5 µg/ml were achieved after the first ravulizumab dose and sustained throughout treatment in both studies. In a minority of patients, free C5 concentrations <0·5 µg/ml were not consistently achieved with eculizumab in either study. Ravulizumab q8w was more consistent in providing immediate, complete, sustained C5 inhibition than eculizumab every-2-weeks in patients with PNH.

Original languageEnglish (US)
JournalBritish journal of haematology
DOIs
StateAccepted/In press - 2020

Keywords

  • L-lactate dehydrogenase
  • complement C5
  • eculizumab
  • half-life
  • ravulizumab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies'. Together they form a unique fingerprint.

  • Cite this

    Peffault de Latour, R., Brodsky, R. A., Ortiz, S., Risitano, A. M., Jang, J. H., Hillmen, P., Kulagin, A. D., Kulasekararaj, A. G., Rottinghaus, S. T., Aguzzi, R., Gao, X., Wells, R. A., & Szer, J. (Accepted/In press). Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. British journal of haematology. https://doi.org/10.1111/bjh.16711